



**SUMMARY OF CHANGES:**

**INSTRUMENT NOS. 44 to 58 OF 2017**

Statements of Principles (SOPs) Nos. 44 to 57 of 2017, and Amendment Determination No. 58 of 2017, were signed by the Chairperson of the Repatriation Medical Authority (the Authority) on 18 August 2017.

The Instruments have been lodged and registered with the Federal Register of Legislation, pursuant to section 15G of the *Legislation Act 2003* (Legislation Act). The day of commencement as specified in each of the Instruments is 18 September 2017. In accordance with the Legislation Act, the Office of Parliamentary Counsel must generally deliver a legislative instrument for laying before each House of the Parliament within six sitting days of that House after the instrument is registered with the instrument's registered explanatory statement. The Instruments and the associated Explanatory Statements registered with the Federal Register of Legislation are available from: <http://www.legislation.gov.au>.

Copies of each Instrument, the associated Explanatory Statement and a list of references relating to each Instrument, are available in accordance with the *Veterans' Entitlements Act 1986* (the VEA), on written request from the RMA Secretariat.

The 'User Guide to the RMA Statements of Principles' explains the meaning and purpose of each section of the new SOP template which commenced in 2015. This document is available on the Authority's website <http://www.rma.gov.au>.

For further information contact:

The Registrar  
Repatriation Medical Authority  
GPO Box 1014  
Brisbane Qld 4001

T +61 7 3815 9404  
F +61 7 3815 9412  
E [info@rma.gov.au](mailto:info@rma.gov.au)

24 August 2017

## SUMMARY OF CHANGES

Instr. No.	Title	Date of Commencement	ICD-10-AM Codes
<b>REVOCATIONS</b>			
44 & 45/2017	influenza	18/09/2017	J09, J10 or J11
46 & 47/2017	malaria	18/09/2017	B50, B51, B52, B53 or B54
48 & 49/2017	alcohol use disorder	18/09/2017	Nil
50 & 51/2017	rheumatoid arthritis	18/09/2017	M05 or M06
<b>DETERMINATIONS</b>			
52 & 53/2017	tooth wear	18/09/2017	K03.0, K03.1 or K03.2
54 & 55/2017	popliteal entrapment syndrome	18/09/2017	Nil
56 & 57/2017	benign paroxysmal positional vertigo	18/09/2017	H81.1
<b>AMENDMENTS</b>			
58/2017	Veterans' Entitlements (Statements of Principles—Cumulative Equivalent Dose) Amendment Determination 2017	18/09/2017	N/A

**SUMMARY OF CHANGES**

<p>44 &amp; 45/2017</p>	<p>influenza</p>	<p>These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 19 October 2016 concerning <i>influenza</i> in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.</p> <p>The contents of these Instruments are in similar terms as the revoked Instruments. Comparing these Instruments and the revoked Instruments, the differences include:</p> <p><b>For RH &amp; BoP SoPs (Instrument Nos. 44 &amp; 45/2017)</b></p> <ul style="list-style-type: none"> <li>• adopting the latest revised Instrument format, which commenced in 2015;</li> <li>• specifying a day of commencement for the Instrument in section 2;</li> <li>• revising the definition of 'influenza' in subsection 7(2);</li> <li>• revising the reference to 'ICD-10-AM code' in subsection 7(4);</li> <li>• revising the factor in subsection 9(1) concerning 'being exposed to the influenza virus';</li> <li>• new factor in subsection 9(2) concerning 'being exposed to an avian influenza virus', for avian influenza only;</li> <li>• new factor in subsection 9(3) concerning 'being exposed to a swine influenza virus', for swine influenza only;</li> <li>• new factor in subsection 9(4) concerning 'inability to obtain influenza vaccination';</li> <li>• new factor in subsection 9(5)(a) concerning 'a medical condition', for severe influenza only;</li> <li>• new factor in subsection 9(5)(b) concerning 'the third trimester of pregnancy or the following six weeks', for severe influenza only;</li> <li>• new definitions of 'being exposed to a swine influenza virus as specified', 'being exposed to an avian influenza virus as specified', 'being exposed to influenza virus as specified', 'chronic renal failure', 'close exposure', 'immunocompromised state as specified', 'immunosuppressive drug', 'medical condition as specified', 'MRCA', 'severe influenza' and 'VEA' in Schedule 1 - Dictionary; and</li> <li>• revising the definitions of 'influenza virus' and 'relevant service' in Schedule 1 - Dictionary.</li> </ul> <p><b>The determining of these Instruments finalises the investigation in relation to <i>influenza</i> as advertised in the Government Notices Gazette of 19 October 2016.</b></p>
<p>46 &amp; 47/2017</p>	<p>malaria</p>	<p>These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 19 October 2016 concerning <i>malaria</i> in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.</p> <p>The contents of these Instruments are in similar terms as the revoked Instruments. Comparing these Instruments and the revoked Instruments, the differences include:</p> <p><b>For RH SoP (Instrument No. 46/2017)</b></p> <ul style="list-style-type: none"> <li>• adopting the latest revised Instrument format, which commenced in 2015;</li> <li>• specifying a day of commencement for the Instrument in section 2;</li> <li>• revising the definition of 'malaria' in subsection 7(2);</li> <li>• revising the reference to 'ICD-10-AM code' in subsection 7(4);</li> <li>• revising the factor in subsection 9(2) concerning 'being exposed to <i>Plasmodium vivax</i> or <i>Plasmodium ovale</i>', by the inclusion of a Note;</li> <li>• revising the factor in subsection 9(3) concerning 'being exposed to <i>Plasmodium malariae</i>, <i>Plasmodium falciparum</i> or simian malaria species';</li> <li>• new factors in subsections 9(4) &amp; 9(6) concerning 'immunocompromised state';</li> <li>• new factor in subsection 9(5) concerning 'being pregnant', for clinical onset;</li> <li>• revising the factor in subsection 9(7) concerning 'being pregnant', for clinical worsening;</li> <li>• new factor in subsection 9(8) concerning 'a systemic infectious disease', for malaria due to <i>Plasmodium vivax</i> or <i>Plasmodium ovale</i> only, for clinical worsening only;</li> <li>• deleting the factor concerning 'human immunodeficiency virus' which is now subsumed by the factor in subsection 9(6) concerning 'immunocompromised state';</li> <li>• new definitions of 'chronic renal failure', 'immunocompromised state as specified', 'immunosuppressive drug', 'MRCA', 'systemic infectious disease as specified' and 'VEA' in Schedule 1 - Dictionary; and</li> <li>• revising the definitions of 'being exposed to <i>Plasmodium malariae</i>, <i>Plasmodium falciparum</i> or simian malaria species as specified' and 'relevant service' in Schedule 1 – Dictionary.</li> </ul>

**SUMMARY OF CHANGES**

		<p><b>For BoP SoP (Instrument No. 47/2017)</b></p> <ul style="list-style-type: none"> <li>• adopting the latest revised Instrument format, which commenced in 2015;</li> <li>• specifying a day of commencement for the Instrument in section 2;</li> <li>• revising the definition of 'malaria' in subsection 7(2);</li> <li>• revising the reference to 'ICD-10-AM code' in subsection 7(4);</li> <li>• revising the factor in subsection 9(2) concerning 'being exposed to <i>Plasmodium vivax</i> or <i>Plasmodium ovale</i>', by the inclusion of a Note;</li> <li>• revising the factor in subsection 9(3) concerning 'being exposed to <i>Plasmodium malariae</i>, <i>Plasmodium falciparum</i> or simian malaria species';</li> <li>• new factor in subsection 9(4) concerning 'human immunodeficiency virus';</li> <li>• new factor in subsection 9(5) concerning 'being pregnant', for clinical onset;</li> <li>• revising the factor in subsection 9(6) concerning 'human immunodeficiency virus', for clinical worsening;</li> <li>• revising the factor in subsection 9(7) concerning 'being pregnant', for clinical worsening;</li> <li>• new definitions of 'MRCA' and 'VEA' in Schedule 1 - Dictionary; and</li> <li>• revising the definitions of 'being exposed to <i>Plasmodium malariae</i>, <i>Plasmodium falciparum</i> or simian malaria species as specified' and 'relevant service' in Schedule 1 – Dictionary.</li> </ul> <p><b>The determining of these Instruments finalises the investigation in relation to malaria as advertised in the Government Notices Gazette of 19 October 2016.</b></p>
<p>48 &amp; 49/2017</p>	<p>alcohol use disorder</p>	<p>These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 3 May 2016 concerning <i>alcohol use disorder</i> in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.</p> <p>The contents of these Instruments are in similar terms as the revoked Instruments. Comparing these Instruments and the revoked Instruments, the differences include:</p> <p><b>For RH SoP (Instrument No. 48/2017)</b></p> <ul style="list-style-type: none"> <li>• adopting the latest revised Instrument format, which commenced in 2015;</li> <li>• specifying a day of commencement for the Instrument in section 2;</li> <li>• revising the definition of 'alcohol use disorder' in subsection 7(2);</li> <li>• new factors in subsections 9(1) &amp; 9(9) concerning 'a clinically significant disorder of mental health as specified';</li> <li>• revising the factors in subsections 9(2) &amp; 9(10) concerning 'a category 1A stressor', by the inclusion of a Note;</li> <li>• revising the factors in subsections 9(3) &amp; 9(11) concerning 'a category 1B stressor', by the inclusion of a Note;</li> <li>• revising the factors in subsections 9(4) &amp; 9(12) concerning 'death of a significant other';</li> <li>• revising the factors in subsections 9(5) &amp; 9(13) concerning 'severe childhood abuse';</li> <li>• new factors in subsections 9(6) &amp; 9(14) concerning 'a category 2 stressor';</li> <li>• new factors in subsections 9(7) &amp; 9(15) concerning 'persistent pain';</li> <li>• new factors in subsections 9(8) &amp; 9(16) concerning 'Roux-en-Y gastric bypass surgery';</li> <li>• deleting the factors concerning 'a clinically significant psychiatric condition' as they are now covered by the factors in subsections 9(1) &amp; 9(9) concerning 'a clinically significant disorder of mental health as specified';</li> <li>• deleting the factors concerning 'a medical illness or injury which is life-threatening or which results in serious physical or cognitive disability';</li> <li>• new definitions of 'category 2 stressor', 'clinically significant disorder of mental health as specified', 'MRCA', 'persistent pain' and 'VEA' in Schedule 1 - Dictionary;</li> <li>• revising the definitions of 'category 1A stressor', 'eyewitness' and 'relevant service' in Schedule 1 - Dictionary; and</li> <li>• deleting the definitions of 'a clinically significant psychiatric condition' and 'a specified disorder of mental health'.</li> </ul> <p><b>For BoP SoP (Instrument No. 49/2017)</b></p> <ul style="list-style-type: none"> <li>• adopting the latest revised Instrument format, which commenced in 2015;</li> <li>• specifying a day of commencement for the Instrument in section 2;</li> <li>• revising the definition of 'alcohol use disorder' in subsection 7(2);</li> <li>• new factors in subsections 9(1) &amp; 9(7) concerning 'a clinically significant disorder of mental health as specified';</li> </ul>

**SUMMARY OF CHANGES**

		<ul style="list-style-type: none"> <li>• revising the factors in subsections 9(2) &amp; 9(8) concerning 'a category 1A stressor', by the inclusion of a Note;</li> <li>• revising the factors in subsections 9(3) &amp; 9(9) concerning 'a category 1B stressor', by the inclusion of a Note;</li> <li>• revising the factors in subsections 9(4) &amp; 9(10) concerning 'death of a significant other';</li> <li>• revising the factors in subsections 9(5) &amp; 9(11) concerning 'severe childhood abuse';</li> <li>• new factors in subsections 9(6) &amp; 9(12) concerning 'a category 2 stressor';</li> <li>• deleting the factors concerning 'a clinically significant psychiatric condition' as they are now covered by the factors in subsections 9(1) &amp; 9(9) concerning 'a clinically significant disorder of mental health as specified';</li> <li>• new definitions of 'category 2 stressor', 'clinically significant disorder of mental health as specified', 'MRCA' and 'VEA' in Schedule 1 - Dictionary;</li> <li>• revising the definitions of 'category 1A stressor', 'eyewitness' and 'relevant service' in Schedule 1 - Dictionary; and</li> <li>• deleting the definitions of 'a clinically significant psychiatric condition' and 'a specified disorder of mental health'.</li> </ul> <p>On 7 April 2017, the Authority wrote to organisations representing veterans, service personnel and their dependants regarding the proposed Instruments concerning alcohol use disorder and the medical-scientific material considered by the Authority. This letter emphasised the deletion of factors relating to <i>a medical illness or injury which is life-threatening or which results in serious physical or cognitive disability</i> from the Reasonable Hypothesis Instrument. The Authority provided an opportunity to the organisations to make representations in relation to the proposed Instruments prior to their determination. No submissions were received for consideration by the Authority. Minor textual changes were made to the proposed Instruments following this consultation process.</p> <p><b>The determining of these Instruments finalises the investigation in relation to alcohol use disorder as advertised in the Government Notices Gazette of 3 May 2016.</b></p>
<p>50 &amp; 51/2017</p>	<p>rheumatoid arthritis</p>	<p>These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 3 May 2016 concerning <i>rheumatoid arthritis</i> in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.</p> <p>The contents of these Instruments are in similar terms as the revoked Instruments. Comparing these Instruments and the revoked Instruments, the differences include:</p> <p><b>For RH SoP (Instrument No. 50/2017)</b></p> <ul style="list-style-type: none"> <li>• adopting the latest revised Instrument format, which commenced in 2015;</li> <li>• specifying a day of commencement for the Instrument in section 2;</li> <li>• revising the definition of 'rheumatoid arthritis' in subsection 7(2);</li> <li>• revising the reference to 'ICD-10-AM code' in subsection 7(4);</li> <li>• revising the factors in subsections 9(1) &amp; 9(8) concerning 'smoking';</li> <li>• new factor in subsection 9(3) concerning 'Specified List 1 of drugs' for clinical onset;</li> <li>• new factors in subsections 9(4) &amp; 9(12) concerning 'periodontitis';</li> <li>• new factors in subsections 9(5) &amp; 9(13) concerning 'being obese';</li> <li>• new factors in subsections 9(6) &amp; 9(14) concerning 'beverages sweetened with high fructose corn syrup';</li> <li>• new factors in subsections 9(7) &amp; 9(15) concerning 'vitamin D deficiency';</li> <li>• new factor in subsection 9(10) concerning 'Specified List 2 of drugs' for clinical worsening;</li> <li>• new factor in subsection 9(11) concerning 'a disease modifying antirheumatic drug' for clinical worsening;</li> <li>• deleting the factor concerning 'mineral oil';</li> <li>• new definitions of 'being obese', 'BMI', 'disease modifying antirheumatic drug', 'MRCA', 'Specified List 1 of drugs', 'Specified List 2 of drugs' and 'VEA' in Schedule 1 - Dictionary;</li> <li>• revising the definitions of 'pack-years of cigarettes, or the equivalent thereof in other tobacco products' and 'relevant service' in Schedule 1 - Dictionary; and</li> <li>• deleting the definitions of 'a drug from specified list 1', 'a drug from specified list 2', 'mineral oil' and 'seropositive rheumatoid arthritis'.</li> </ul> <p><b>For BoP SoP (Instrument No. 51/2017)</b></p>

**SUMMARY OF CHANGES**

		<ul style="list-style-type: none"> <li>• adopting the latest revised Instrument format, which commenced in 2015;</li> <li>• specifying a day of commencement for the Instrument in section 2;</li> <li>• revising the definition of 'rheumatoid arthritis' in subsection 7(2);</li> <li>• revising the reference to 'ICD-10-AM code' in subsection 7(4);</li> <li>• revising the factors in subsections 9(1) &amp; 9(6) concerning 'smoking';</li> <li>• new factors in subsections 9(3) &amp; 9(8) concerning 'specified list of drugs' for clinical onset;</li> <li>• new factors in subsections 9(4) &amp; 9(10) concerning 'periodontitis';</li> <li>• new factors in subsections 9(5) &amp; 9(11) concerning 'being obese';</li> <li>• new factor in subsection 9(9) concerning 'a disease modifying antirheumatic drug' for clinical worsening;</li> <li>• new definitions of 'being obese', 'BMI', 'disease modifying antirheumatic drug', 'MRCA', 'specified list of drugs' and 'VEA' in Schedule 1 Dictionary;</li> <li>• revising the definitions of 'pack-years of cigarettes, or the equivalent thereof in other tobacco products' and 'relevant service' in Schedule 1 - Dictionary; and</li> <li>• deleting the definition of 'seropositive rheumatoid arthritis'.</li> </ul> <p>On 7 April 2017, the Authority wrote to organisations representing veterans, service personnel and their dependants regarding the proposed Instruments concerning rheumatoid arthritis and the medical-scientific material considered by the Authority. This letter emphasised the deletion of factors relating to <i>inhaling, ingesting or having cutaneous contact with mineral oil, for seropositive rheumatoid arthritis only</i>, from the Reasonable Hypothesis Instrument. The Authority provided an opportunity to the organisations to make representations in relation to the proposed Instruments prior to their determination. No submissions were received for consideration by the Authority. Minor textual changes were made to the proposed Instruments following this consultation process.</p> <p><b>The determining of these Instruments finalises the investigation in relation to <i>rheumatoid arthritis</i> as advertised in the Government Notices Gazette of 3 May 2016.</b></p>
52 & 53/2017	tooth wear	<p><b>New Condition</b></p> <p><b>The determining of these new Instruments finalises the investigation in relation to <i>tooth wear</i> as advertised in the Government Notices Gazette of 19 October 2016.</b></p>
54 & 55/2017	popliteal entrapment syndrome	<p><b>New Condition</b></p> <p><b>The determining of these new Instruments finalises the investigation in relation to <i>popliteal entrapment syndrome</i> as advertised in the Government Notices Gazette of 10 January 2017.</b></p>
56 & 57/2017	benign paroxysmal positional vertigo	<p><b>New Condition</b></p> <p><b>The determining of these new Instruments finalises the investigation in relation to <i>benign paroxysmal positional vertigo</i> as advertised in the Government Notices Gazette of 10 January 2017.</b></p>
58/2017	various Statements of Principles	<p><b>Amendments</b></p> <p>This instrument amends the 124 Statements of Principles in Schedule 1 attached, by:</p> <ul style="list-style-type: none"> <li>• omitting the existing definition of 'cumulative equivalent dose' contained in each of those Statements of Principles;</li> <li>• substituting the definition of 'cumulative equivalent dose' contained in paragraph 1 of Parts 1 and 2 of the Schedule 1-Amendments to this Instrument; and</li> <li>• specifying the day of commencement of these amendments.</li> </ul> <p><b>The determining of this Instrument finalises the investigation in relation to <i>the definition of the term 'cumulative equivalent dose' referred to in the ionising radiation factor in the Statements of Principles for the kinds of injury, disease or death listed in Schedule 1 below</i>, as advertised in the Government Notices Gazette of 10 February 2017.</b></p>

## Schedule 1

<b>Statement of Principles</b>	<b>Instrument No.</b>	<b>Ionising Radiation Factor No.</b>	<b>Definition of "cumulative equivalent dose" reference</b>
acoustic neuroma	29 of 2011	6(a)	Paragraph 9
acoustic neuroma	30 of 2011	6(a)	Paragraph 9
acquired cataract	87 of 2016	9(4)	Schedule 1 - Dictionary
acquired cataract	88 of 2016	9(4)	Schedule 1 - Dictionary
acute lymphoblastic leukaemia	75 of 2012, as amended	6(a)	Paragraph 9
acute lymphoblastic leukaemia	76 of 2012	6(a)	Paragraph 9
acute myeloid leukaemia	71 of 2015, as amended	9(4)	Schedule 1 - Dictionary
acute myeloid leukaemia	72 of 2015, as amended	9(4)	Schedule 1 - Dictionary
adenocarcinoma of the kidney	9 of 2013	6(l)	Paragraph 9
adenocarcinoma of the kidney	10 of 2013	6(f)	Paragraph 9
Alzheimer-type dementia	22 of 2010, as amended	6(jb)	Paragraph 9
angle-closure glaucoma	25 of 2012	6(i) & 6(r)	Paragraph 9
angle-closure glaucoma	26 of 2012	6(i) & 6(r)	Paragraph 9
aortic stenosis	21 of 2013	6(c) & 6(n)	Paragraph 9
aortic stenosis	22 of 2013	6(c) & 6(j)	Paragraph 9
atherosclerotic peripheral vascular disease	23 of 2012	6(g) & 6(q)	Paragraph 9
atherosclerotic peripheral vascular disease	24 of 2012	6(g) & 6(o)	Paragraph 9
benign neoplasm of the eye and adnexa	41 of 2016	9(3)	Schedule 1 - Dictionary
benign neoplasm of the eye and adnexa	42 of 2016	9(2)	Schedule 1 - Dictionary
cardiomyopathy	85 of 2015	9(24) & 9(55)	Schedule 1 - Dictionary
cardiomyopathy	86 of 2015	9(21) & 9(49)	Schedule 1 - Dictionary
carotid arterial disease	37 of 2012	6(i) & 6(aa)	Paragraph 9
carotid arterial disease	38 of 2012	6(h) & 6(w)	Paragraph 9
cerebral meningioma	19 of 2009, as amended	6(a)	Paragraph 9
cerebral meningioma	20 of 2009, as amended	6(a)	Paragraph 9
cerebrovascular accident	65 of 2015	6(pp)(xv)	Paragraph 9
cerebrovascular accident	66 of 2015	6(ff)(xv)	Paragraph 9
chronic gastritis and chronic gastropathy	25 of 2013	6(b)(vi) & 6(i)	Paragraph 9
chronic gastritis and chronic gastropathy	26 of 2013	6(b)(vi) & 6(i)	Paragraph 9
chronic myeloid leukaemia	47 of 2014	6(b)	Paragraph 9
chronic myeloid leukaemia	48 of 2014	6(b)	Paragraph 9
chronic pancreatitis	104 of 2011	6(c)	Paragraph 9
chronic pancreatitis	105 of 2011	6(c)	Paragraph 9
cirrhosis of the liver	1 of 2017	9(3) & 9(30)	Schedule 1 - Dictionary
erectile dysfunction	43 of 2013	6(g) & 6(aa)	Paragraph 9
erectile dysfunction	44 of 2013	6(g) & 6(z)	Paragraph 9
external burn	110 of 2015	9(4)	Schedule 1 - Dictionary
external burn	111 of 2015	9(4)	Schedule 1 - Dictionary
fibrosing interstitial lung disease	53 of 2013	6(n) & 6(jj)	Paragraph 9
fibrosing interstitial lung disease	54 of 2013	6(n) & 6(jj)	Paragraph 9
gastric ulcer and duodenal ulcer	61 of 2015	6(l) & 6(ff)	Paragraph 9
gastric ulcer and duodenal ulcer	62 of 2015	6(j) & 6(v)	Paragraph 9
goitre	23 of 2013	6(i)(i) & 6(s)(i)	Paragraph 9
goitre	24 of 2013	6(i)(i) & 6(r)(i)	Paragraph 9
Graves' disease	33 of 2013	6(d) & 6(k)	Paragraph 9
Graves' disease	34 of 2013	6(d) & 6(k)	Paragraph 9
Hashimoto's thyroiditis	31 of 2013	6(d) & 6(j)	Paragraph 9
Hashimoto's thyroiditis	32 of 2013	6(d) & 6(i)	Paragraph 9
heart block	1 of 2014	6(o) & 6(jj)	Paragraph 9

heart block	2 of 2014	6(o) & 6(ii)	Paragraph 9
hypothyroidism	29 of 2013	6(h) & 6w)	Paragraph 9
hypothyroidism	30 of 2013	6(h) & 6(v)	Paragraph 9
ischaemic heart disease	1 of 2016	9(17) & 9(60)	Schedule 1 - Dictionary
ischaemic heart disease	2 of 2016	9(15) & 9(48)	Schedule 1 - Dictionary
malignant neoplasm of the bile duct	69 of 2015	6(e)	Paragraph 9
malignant neoplasm of the bile duct	70 of 2015	6(e)	Paragraph 9
malignant neoplasm of the bladder	96 of 2011	6(b)	Paragraph 9
malignant neoplasm of the bladder	97 of 2011	6(b)	Paragraph 9
malignant neoplasm of bone and articular cartilage	106 of 2011	6(a)	Paragraph 9
malignant neoplasm of bone and articular cartilage	107 of 2011	6(a)	Paragraph 9
malignant neoplasm of the brain	85 of 2016	9(1)	Schedule 1 – Dictionary
malignant neoplasm of the brain	86 of 2016	9(1)	Schedule 1 - Dictionary
malignant neoplasm of the breast	96 of 2014	6(a)	Paragraph 9
malignant neoplasm of the breast	97 of 2014	6(a)	Paragraph 9
malignant neoplasm of the cerebral meninges	21 of 2009, as amended	6(a)	Paragraph 9
malignant neoplasm of the cerebral meninges	22 of 2009, as amended	6(a)	Paragraph 9
malignant neoplasm of the colorectum	37 of 2013	6(i)	Paragraph 9
malignant neoplasm of the colorectum	38 of 2013	6(g)	Paragraph 9
malignant neoplasm of the endometrium	11 of 2016	9(12)	Schedule 1 – Dictionary
malignant neoplasm of the endometrium	12 of 2016	9(11)	Schedule 1 - Dictionary
malignant neoplasm of the gallbladder	89 of 2015	9(4)	Schedule 1 – Dictionary
malignant neoplasm of the gallbladder	90 of 2015	9(4)	Schedule 1 – Dictionary
malignant neoplasm of the liver	21 of 2011	6(g)	Paragraph 9
malignant neoplasm of the liver	22 of 2011	6(g)	Paragraph 9
malignant neoplasm of the lung	92 of 2014	6(k)	Paragraph 9
malignant neoplasm of the lung	93 of 2014	6(h)	Paragraph 9
malignant neoplasm of the oesophagus	120 of 2015, as amended	9(3)	Schedule 1 – Dictionary
malignant neoplasm of the oesophagus	121 of 2015	9(3)	Schedule 1 – Dictionary
malignant neoplasm of the ovary	70 of 2009, as amended	6(i)	Paragraph 9
malignant neoplasm of the ovary	71 of 2009, as amended	6(d)	Paragraph 9
malignant neoplasm of the renal pelvis and ureter	98 of 2011	6(b)	Paragraph 9
malignant neoplasm of the renal pelvis and ureter	99 of 2011	6(b)	Paragraph 9
malignant neoplasm of the salivary gland	57 of 2015	6(a)	Paragraph 9
malignant neoplasm of the salivary gland	58 of 2015	6(a) & 6(b)	Paragraph 9
malignant neoplasm of the stomach	58 of 2014	6(b)	Paragraph 9
malignant neoplasm of the stomach	59 of 2014	6(b)	Paragraph 9
malignant neoplasm of the thyroid gland	39 of 2014	6(a)	Paragraph 9
malignant neoplasm of the thyroid gland	40 of 2014	6(a) & 6(b)	Paragraph 9
malignant neoplasm of unknown primary site	80 of 2014	6(c)	Paragraph 9
malignant neoplasm of unknown primary site	81 of 2014	6(b)	Paragraph 9
mesothelioma	104 of 2015	9(4)	Schedule 1 – Dictionary
mesothelioma	105 of 2015	9(4)	Schedule 1 – Dictionary
multiple sclerosis	100 of 2011	6(s)	Paragraph 9
myelodysplastic syndrome	73 of 2015, as amended	9(3)	Schedule 1 – Dictionary
myelodysplastic syndrome	74 of 2015, as amended	9(3)	Schedule 1 – Dictionary
myeloma	69 of 2012, as amended	6(a)	Paragraph 9



narcolepsy	7 of 2014	6(d)	Paragraph 9
narcolepsy	8 of 2014	6(d)	Paragraph 9
neoplasm of the pituitary gland	53 of 2015	6(a)	Paragraph 9
non-aneurysmal aortic atherosclerotic disease	15 of 2012	6(f) & 6(q)	Paragraph 9
non-aneurysmal aortic atherosclerotic disease	16 of 2012	6(f) & 6(m)	Paragraph 9
non-Hodgkin's lymphoma	28 of 2010, as amended	6(va)	Paragraph 9
non-melanotic malignant neoplasm of the skin	7 of 2016	9(5)	Schedule 1 – Dictionary
non-melanotic malignant neoplasm of the skin	8 of 2016	9(3)(b)	Schedule 1 – Dictionary
open-angle glaucoma	27 of 2012	6(h) & 6(t)	Paragraph 9
open-angle glaucoma	28 of 2012	6(h) & 6(t)	Paragraph 9
optochiasmatic arachnoiditis	57 of 2016	9(6) & 9(14)	Schedule 1 – Dictionary
optochiasmatic arachnoiditis	58 of 2016	9(6) & 9(14)	Schedule 1 – Dictionary
osteomyelitis	90 of 2014	6(j)	Paragraph 9
osteomyelitis	91 of 2014	6(j)	Paragraph 9
otitis externa	58 of 2012	6(c) & 6(o)	Paragraph 9
otitis externa	59 of 2012	6(c) & 6(o)	Paragraph 9
otitis media	51 of 2014	6(e)	Paragraph 9
otitis media	52 of 2014	6(e)	Paragraph 9
peritoneal adhesions	3 of 2016	9(8)	Schedule 1 – Dictionary
peritoneal adhesions	4 of 2016	9(8)	Schedule 1 – Dictionary
renal artery atherosclerotic disease	102 of 2011	6(f) & 6(m)	Paragraph 9
renal artery atherosclerotic disease	103 of 2011	6(f) & 6(m)	Paragraph 9
soft tissue sarcoma	5 of 2015	6(c) & 6(d)(i)	Paragraph 9
soft tissue sarcoma	6 of 2015	6(b) & 6(c)(i)	Paragraph 9
tinnitus	33 of 2012	6(m) & 6(ee)	Paragraph 9
tinnitus	34 of 2012	6(m) & 6(dd)	Paragraph 9
trigeminal neuropathy	79 of 2015	9(22) & 9(50)	Schedule 1 – Dictionary
trigeminal neuropathy	80 of 2015	9(22) & 9(47)	Schedule 1 – Dictionary